{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T07:14:41Z","timestamp":1778656481175,"version":"3.51.4"},"reference-count":76,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,9,20]],"date-time":"2021-09-20T00:00:00Z","timestamp":1632096000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["WT107963AIA"],"award-info":[{"award-number":["WT107963AIA"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012317","name":"UCLH Biomedical Research Centre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012317","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000351","name":"British Lung Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000351","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["536993 K71"],"award-info":[{"award-number":["536993 K71"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jbc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Biological Chemistry"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.jbc.2021.101223","type":"journal-article","created":{"date-parts":[[2021,9,29]],"date-time":"2021-09-29T00:33:58Z","timestamp":1632875638000},"page":"101223","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["BAP1 and YY1 regulate expression of death receptors in malignant pleural mesothelioma"],"prefix":"10.1016","volume":"297","author":[{"given":"Yuki","family":"Ishii","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Krishna K.","family":"Kolluri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adam","family":"Pennycuick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xidan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ersilia","family":"Nigro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Doraid","family":"Alrifai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elaine","family":"Borg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary","family":"Falzon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Khalid","family":"Shah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neelam","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6634-5939","authenticated-orcid":false,"given":"Sam M.","family":"Janes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jbc.2021.101223_bib1","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","article-title":"Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma","volume":"21","author":"Vogelzang","year":"2003","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.jbc.2021.101223_bib2","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.3389\/fonc.2019.01519","article-title":"Malignant pleural mesothelioma: State-of-the-art on current therapies and promises for the future","volume":"9","author":"Nicolini","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1016\/j.jbc.2021.101223_bib3","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.lungcan.2017.03.005","article-title":"Targeting BAP1: A new paradigm for mesothelioma","volume":"109","author":"Schunselaar","year":"2017","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jbc.2021.101223_bib4","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1136\/jclinpath-2016-203866","article-title":"BAP1: Gene of the month","volume":"69","author":"Wang","year":"2016","journal-title":"J.\u00a0Clin. Pathol."},{"key":"10.1016\/j.jbc.2021.101223_bib5","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/nrc3459","article-title":"BAP1 and cancer","volume":"13","author":"Carbone","year":"2013","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.jbc.2021.101223_bib6","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1038\/ng.855","article-title":"The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma","volume":"43","author":"Bott","year":"2011","journal-title":"Nat. Genet."},{"key":"10.1016\/j.jbc.2021.101223_bib7","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1097\/JTO.0000000000000471","article-title":"High incidence of somatic BAP1 alterations in sporadic malignant mesothelioma","volume":"10","author":"Nasu","year":"2015","journal-title":"J.\u00a0Thorac. Oncol."},{"key":"10.1016\/j.jbc.2021.101223_bib8","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1097\/JTO.0000000000000436","article-title":"Targeted next-generation sequencing of cancer genes in advanced stage malignant pleural mesothelioma: A retrospective study","volume":"10","author":"Lo Iacono","year":"2015","journal-title":"J.\u00a0Thorac. Oncol."},{"key":"10.1016\/j.jbc.2021.101223_bib9","doi-asserted-by":"crossref","first-page":"2498","DOI":"10.1158\/1535-7163.MCT-16-0229","article-title":"Genomic landscape of malignant mesotheliomas","volume":"15","author":"Kato","year":"2016","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.jbc.2021.101223_bib10","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1016\/j.jtho.2016.06.020","article-title":"BRCA1-associated protein 1 (BAP1) immunohistochemical expression as a diagnostic tool in malignant pleural mesothelioma classification: A large retrospective study","volume":"11","author":"Righi","year":"2016","journal-title":"J.\u00a0Thorac. Oncol."},{"key":"10.1016\/j.jbc.2021.101223_bib11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12885-018-5079-x","article-title":"Comparison of germline versus somatic BAP1 mutations for risk of metastasis in uveal melanoma","volume":"18","author":"Ewens","year":"2018","journal-title":"BMC Cancer"},{"key":"10.1016\/j.jbc.2021.101223_bib12","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.ccell.2017.07.003","article-title":"Integrative analysis identifies four molecular and clinical subsets in uveal melanoma","volume":"32","author":"Robertson","year":"2017","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jbc.2021.101223_bib13","doi-asserted-by":"crossref","first-page":"100800","DOI":"10.1016\/j.preteyeres.2019.100800","article-title":"Uveal melanoma: Towards a molecular understanding","volume":"75","author":"Smit","year":"2020","journal-title":"Prog. Retin. Eye Res."},{"key":"10.1016\/j.jbc.2021.101223_bib14","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1038\/ng.2813","article-title":"Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas","volume":"45","author":"Jiao","year":"2013","journal-title":"Nat. Genet."},{"key":"10.1016\/j.jbc.2021.101223_bib15","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000002491","article-title":"Loss of BAP1 expression occurs frequently in intrahepatic cholangiocarcinoma","volume":"95","author":"Andrici","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.jbc.2021.101223_bib16","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1111\/his.13127","article-title":"Intrahepatic cholangiocarcinoma frequently shows loss of BAP1 and PBRM1 expression, and demonstrates specific clinicopathological and genetic characteristics with BAP1 loss","volume":"70","author":"Misumi","year":"2017","journal-title":"Histopathology"},{"key":"10.1016\/j.jbc.2021.101223_bib17","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/s41581-020-0301-x","article-title":"Genomic profiling in renal cell carcinoma","volume":"16","author":"Dizman","year":"2020","journal-title":"Nat. Rev. Nephrol."},{"key":"10.1016\/j.jbc.2021.101223_bib18","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1002\/cncr.28521","article-title":"Loss of BAP1 protein expression is an independent marker of poor prognosis in patients with low-risk clear cell renal cell carcinoma","volume":"120","author":"Joseph","year":"2014","journal-title":"Cancer"},{"key":"10.1016\/j.jbc.2021.101223_bib19","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1038\/ng.2323","article-title":"BAP1 loss defines a new class of renal cell carcinoma","volume":"44","author":"Pe\u00f1a-Llopis","year":"2012","journal-title":"Nat. Genet."},{"key":"10.1016\/j.jbc.2021.101223_bib20","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1038\/nm.3947","article-title":"Loss of BAP1 function leads to EZH2-dependent transformation","volume":"21","author":"Lafave","year":"2015","journal-title":"Nat. Med."},{"key":"10.1016\/j.jbc.2021.101223_bib21","doi-asserted-by":"crossref","first-page":"9058","DOI":"10.1200\/JCO.2020.38.15_suppl.9058","article-title":"Safety and efficacy of tazemetostat, an enhancer of zeste-homolog 2 inhibitor, in patients with relapsed or refractory malignant mesothelioma","volume":"38","author":"Zauderer","year":"2020","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.jbc.2021.101223_bib22","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1038\/nature22798","article-title":"BAP1 regulates IP3R3-mediated Ca 2+ flux to mitochondria suppressing cell transformation","volume":"546","author":"Bononi","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.jbc.2021.101223_bib23","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.30224","article-title":"Loss of functional BAP1 augments sensitivity to TRAIL in cancer cells","volume":"7","author":"Kolluri","year":"2018","journal-title":"Elife"},{"key":"10.1016\/j.jbc.2021.101223_bib24","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/S1074-7613(00)80212-5","article-title":"Apo2L\/TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5","volume":"12","author":"Kischkel","year":"2000","journal-title":"Immunity"},{"key":"10.1016\/j.jbc.2021.101223_bib25","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1517\/14728222.2010.519701","article-title":"TRAIL receptor signaling and therapeutics","volume":"14","author":"Abdulghani","year":"2010","journal-title":"Expert Opin. Ther. Targets"},{"key":"10.1016\/j.jbc.2021.101223_bib26","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1038\/nrc.2017.28","article-title":"Exploring the TRAILs less travelled: TRAIL in cancer biology and therapy","volume":"17","author":"Von Karstedt","year":"2017","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.jbc.2021.101223_bib27","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1172\/JCI6926","article-title":"Safety and antitumor activity of recombinant soluble Apo2 ligand","volume":"104","author":"Ashkenazi","year":"1999","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.jbc.2021.101223_bib28","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/5517","article-title":"Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in\u00a0vivo","volume":"5","author":"Walczak","year":"1999","journal-title":"Nat. Med."},{"key":"10.1016\/j.jbc.2021.101223_bib29","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.tips.2014.07.004","article-title":"Targeting death receptors for TRAIL by agents designed by Mother Nature","volume":"35","author":"Prasad","year":"2014","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.jbc.2021.101223_bib30","doi-asserted-by":"crossref","first-page":"2390","DOI":"10.1158\/1078-0432.CCR-06-0352","article-title":"Tumor necrosis factor-related apoptosis-inducing ligand pathway and its therapeutic implications","volume":"12","author":"De Vries","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jbc.2021.101223_bib31","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.bcp.2014.08.010","article-title":"Two death-inducing human TRAIL receptors to target in cancer: Similar or distinct regulation and function?","volume":"91","author":"Van Roosmalen","year":"2014","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.jbc.2021.101223_bib32","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1038\/cdd.2014.81","article-title":"Getting TRAIL back on track for cancer therapy","volume":"21","author":"Lemke","year":"2014","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.jbc.2021.101223_bib33","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1172\/JCI80420","article-title":"Targeting the extrinsic apoptotic pathway in cancer: Lessons learned and future directions","volume":"125","author":"Ashkenazi","year":"2015","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.jbc.2021.101223_bib34","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1038\/cdd.2015.174","article-title":"Onto better TRAILs for cancer treatment","volume":"23","author":"De Miguel","year":"2016","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.jbc.2021.101223_bib35","doi-asserted-by":"crossref","first-page":"104716","DOI":"10.1016\/j.phrs.2020.104716","article-title":"TRAIL in oncology: From recombinant TRAIL to nano- and self-targeted TRAIL-based therapies","volume":"155","author":"Dianat-Moghadam","year":"2020","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.jbc.2021.101223_bib36","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1038\/sj.cgt.7700792","article-title":"Mechanisms of resistance to TRAIL-induced apoptosis in cancer","volume":"12","author":"Zhang","year":"2005","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.jbc.2021.101223_bib37","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/j.trecan.2020.06.006","article-title":"TRAIL of hope meeting resistance in cancer","volume":"6","author":"Deng","year":"2020","journal-title":"Trends Cancer"},{"key":"10.1016\/j.jbc.2021.101223_bib38","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.lungcan.2018.12.004","article-title":"Retrospective response analysis of BAP1 expression to predict the clinical activity of systemic cytotoxic chemotherapy in mesothelioma","volume":"127","author":"Kumar","year":"2019","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jbc.2021.101223_bib39","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1136\/thoraxjnl-2015-207496","article-title":"MesobanK UK: An international mesothelioma bioresource","volume":"71","author":"Rintoul","year":"2016","journal-title":"Thorax"},{"key":"10.1016\/j.jbc.2021.101223_bib40","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1038\/cdd.2015.165","article-title":"Molecular profiling reveals primary mesothelioma cell lines recapitulate human disease","volume":"23","author":"Chernova","year":"2016","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.jbc.2021.101223_bib41","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.lungcan.2012.03.008","article-title":"Overexpression and potential targeting of the oncofoetal antigen 5T4 in malignant pleural mesothelioma","volume":"77","author":"Al-Taei","year":"2012","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jbc.2021.101223_bib42","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1038\/s41419-018-1160-2","article-title":"Sensitization of glioblastoma cells to TRAIL-induced apoptosis by IAP- and Bcl-2 antagonism","volume":"9","author":"Lincoln","year":"2018","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.jbc.2021.101223_bib43","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1016\/j.bbrc.2006.10.163","article-title":"Acquired TRAIL resistance in human breast cancer cells are caused by the sustained cFLIPL and XIAP protein levels and ERK activation","volume":"351","author":"Lee","year":"2006","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.jbc.2021.101223_bib44","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2013.51","article-title":"Upregulation of c-FLIP-short in response to TRAIL promotes survival of NSCLC cells, which could be suppressed by inhibition of Ca2+\/calmodulin signaling","volume":"4","author":"Kaminskyy","year":"2013","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.jbc.2021.101223_bib45","doi-asserted-by":"crossref","first-page":"G129","DOI":"10.1152\/ajpgi.00242.2005","article-title":"Trail induces cell migration and invasion in apoptosis-resistant cholangiocarcinoma cells","volume":"290","author":"Ishimura","year":"2006","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"10.1016\/j.jbc.2021.101223_bib46","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1016\/j.biocel.2007.02.007","article-title":"TRAIL signalling: Decisions between life and death","volume":"39","author":"Falschlehner","year":"2007","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"10.1016\/j.jbc.2021.101223_bib47","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/S0960-9822(06)00297-1","article-title":"TRICK2, a new alternatively spliced receptor that transduces the cytotoxic signal from TRAIL","volume":"7","author":"Screaton","year":"1997","journal-title":"Curr. Biol."},{"key":"10.1016\/j.jbc.2021.101223_bib48","doi-asserted-by":"crossref","first-page":"21265","DOI":"10.1074\/jbc.M111.306480","article-title":"Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) induces death receptor 5 networks that are highly organized","volume":"287","author":"Valley","year":"2012","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.jbc.2021.101223_bib49","doi-asserted-by":"crossref","first-page":"D941","DOI":"10.1093\/nar\/gky1015","article-title":"Cosmic: The catalogue of somatic mutations in cancer","volume":"47","author":"Tate","year":"2019","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.jbc.2021.101223_bib50","doi-asserted-by":"crossref","first-page":"2818","DOI":"10.1038\/onc.2012.304","article-title":"Real-time imaging of the dynamics of death receptors and therapeutics that overcome TRAIL resistance in tumors","volume":"32","author":"Bagci-Onder","year":"2013","journal-title":"Oncogene"},{"key":"10.1016\/j.jbc.2021.101223_bib51","doi-asserted-by":"crossref","first-page":"2216","DOI":"10.1111\/j.1582-4934.2010.01211.x","article-title":"Targeting AML through DR4 with a novel variant of rhTRAIL","volume":"15","author":"Szegezdi","year":"2011","journal-title":"J.\u00a0Cell. Mol. Med."},{"key":"10.1016\/j.jbc.2021.101223_bib52","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.3109\/10428194.2011.567317","article-title":"Death receptor 4 is preferentially recruited to lipid rafts in chronic lymphocytic leukemia cells contributing to tumor necrosis related apoptosis inducing ligand-induced synergistic apoptotic responses","volume":"52","author":"Xiao","year":"2011","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.jbc.2021.101223_bib53","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1007\/s00109-010-0619-0","article-title":"TRAIL signaling is mediated by DR4 in pancreatic tumor cells despite the expression of functional DR5","volume":"88","author":"Lemke","year":"2010","journal-title":"J.\u00a0Mol. Med."},{"key":"10.1016\/j.jbc.2021.101223_bib54","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/1471-2407-11-39","article-title":"Modulation of TRAIL resistance in colon carcinoma cells: Different contributions of DR4 and DR5","volume":"11","author":"Van Geelen","year":"2011","journal-title":"BMC Cancer"},{"key":"10.1016\/j.jbc.2021.101223_bib55","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1158\/1535-7163.MCT-06-0521","article-title":"Chemotherapeutic drugs sensitize cancer cells to TRAIL-mediated apoptosis: Up-regulation of DR5 and inhibition of Yin Yang 1","volume":"6","author":"Baritaki","year":"2007","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.jbc.2021.101223_bib56","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.niox.2008.08.001","article-title":"Nitric oxide sensitizes tumor cells to TRAIL-induced apoptosis via inhibition of the DR5 transcription repressor Yin Yang 1","volume":"20","author":"Huerta-Yepez","year":"2009","journal-title":"Nitric Oxide"},{"key":"10.1016\/j.jbc.2021.101223_bib57","doi-asserted-by":"crossref","first-page":"5071","DOI":"10.1128\/MCB.00396-10","article-title":"The ubiquitin carboxyl hydrolase BAP1 forms a ternary complex with YY1 and HCF-1 and is a critical regulator of gene expression","volume":"30","author":"Yu","year":"2010","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.jbc.2021.101223_bib58","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s13058-019-1116-1","article-title":"MEDI3039, a novel highly potent tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) receptor 2 agonist, causes regression of orthotopic tumors and inhibits outgrowth of metastatic triple-negative breast cancer","volume":"21","author":"Greer","year":"2019","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.jbc.2021.101223_bib59","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1074\/jbc.M114.609834","article-title":"BRCA1-associated protein 1 (BAP1) deubiquitinase antagonizes the ubiquitin-mediated activation of FoxK2 target genes","volume":"290","author":"Okino","year":"2015","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.jbc.2021.101223_bib60","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1158\/1541-7786.MCR-04-0136","article-title":"Contribution of epigenetic silencing of tumor necrosis factor-related apoptosis inducing ligand receptor 1 (DR4) to TRAIL resistance and ovarian cancer","volume":"3","author":"Horak","year":"2005","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.jbc.2021.101223_bib61","doi-asserted-by":"crossref","first-page":"5457","DOI":"10.1158\/1078-0432.CCR-09-1125","article-title":"Epigenetic silencing of death receptor 4 mediates tumor necrosis factor-related apoptosis-inducing ligand resistance in gliomas","volume":"15","author":"Elias","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jbc.2021.101223_bib62","doi-asserted-by":"crossref","first-page":"35829","DOI":"10.1074\/jbc.M405538200","article-title":"Deficient tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) death receptor transport to the cell surface in human colon cancer cells selected for resistance to TRAIL-induced apoptosis","volume":"279","author":"Jin","year":"2004","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.jbc.2021.101223_bib63","doi-asserted-by":"crossref","first-page":"2792","DOI":"10.4161\/cc.10.16.16952","article-title":"Mcl-1 and YY1 inhibition and induction of DR5 by the BH3-mimetic obatoclax (GX15-070) contribute in the sensitization of B-NHL cells to TRAIL apoptosis","volume":"10","author":"Mart\u00ednez-Paniagua","year":"2011","journal-title":"Cell Cycle"},{"key":"10.1016\/j.jbc.2021.101223_bib64","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/s41420-021-00406-2","article-title":"Emerging multifaceted roles of BAP1 complexes in biological processes","volume":"7","author":"Szczepanski","year":"2021","journal-title":"Cell Death Discov."},{"key":"10.1016\/j.jbc.2021.101223_bib65","doi-asserted-by":"crossref","first-page":"2512","DOI":"10.1158\/0008-5472.CAN-19-2415","article-title":"YAP-mediated recruitment of YY1 and EZH2 represses transcription of key cell-cycle regulators","volume":"80","author":"Hoxha","year":"2020","journal-title":"Cancer Res."},{"key":"10.1016\/j.jbc.2021.101223_bib66","doi-asserted-by":"crossref","first-page":"75","DOI":"10.4049\/jimmunol.167.1.75","article-title":"Nitric oxide inhibits the transcription repressor Yin-Yang 1 binding activity at the silencer region of the Fas promoter: A pivotal role for nitric oxide in the up-regulation of Fas gene expression in human tumor cells","volume":"167","author":"Garb\u00e1n","year":"2001","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.jbc.2021.101223_bib67","doi-asserted-by":"crossref","first-page":"2174","DOI":"10.4049\/jimmunol.175.4.2174","article-title":"Rituximab-induced inhibition of YY1 and Bcl-x L expression in Ramos non-Hodgkin\u2019s lymphoma cell line via inhibition of NF-\u03baB activity: Role of YY1 and Bcl-x L in Fas resistance and chemoresistance, respectively","volume":"175","author":"Vega","year":"2005","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.jbc.2021.101223_bib68","doi-asserted-by":"crossref","first-page":"8114","DOI":"10.1038\/sj.onc.1208954","article-title":"Rituximab (chimeric anti-CD20) sensitizes B-NHL cell lines to Fas-induced apoptosis","volume":"24","author":"Vega","year":"2005","journal-title":"Oncogene"},{"key":"10.1016\/j.jbc.2021.101223_bib69","doi-asserted-by":"crossref","first-page":"8471","DOI":"10.1038\/ncomms9471","article-title":"BAP1 promotes breast cancer cell proliferation and metastasis by deubiquitinating KLF5","volume":"6","author":"Qin","year":"2015","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jbc.2021.101223_bib70","doi-asserted-by":"crossref","first-page":"112506","DOI":"10.1016\/j.yexcr.2021.112506","article-title":"BAP1 antagonizes WWP1-mediated transcription factor KLF5 ubiquitination and inhibits autophagy to promote melanoma progression","volume":"402","author":"Jia","year":"2021","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.jbc.2021.101223_bib71","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1158\/1078-0432.CCR-17-1573","article-title":"BAP1 is a novel target in HPV-negative head and neck cancer","volume":"24","author":"Liu","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jbc.2021.101223_bib72","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1038\/s41375-018-0126-9","article-title":"Reduced BAP1 activity prevents ASXL1 truncation-driven myeloid malignancy in\u00a0vivo","volume":"32","author":"Guo","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.jbc.2021.101223_bib73","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1002\/ijc.31255","article-title":"The Yin and Yang of YY1 in tumor growth and suppression","volume":"143","author":"Khachigian","year":"2018","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.jbc.2021.101223_bib74","doi-asserted-by":"crossref","first-page":"4183","DOI":"10.7150\/thno.43481","article-title":"The biological implications of Yin Yang 1 in the hallmarks of cancer","volume":"10","author":"Meliala","year":"2020","journal-title":"Theranostics"},{"key":"10.1016\/j.jbc.2021.101223_bib75","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1136\/thoraxjnl-2015-207429","article-title":"Exploration of a potent PI3 kinase\/mTOR inhibitor as a novel anti-fibrotic agent in IPF","volume":"71","author":"Mercer","year":"2016","journal-title":"Thorax"},{"key":"10.1016\/j.jbc.2021.101223_bib76","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1164\/rccm.201507-1414OC","article-title":"Rapid expansion of human epithelial stem cells suitable for airway tissue engineering","volume":"194","author":"Butler","year":"2016","journal-title":"Am. J. Respir. Crit. Care Med."}],"container-title":["Journal of Biological Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021925821010267?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021925821010267?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T06:52:10Z","timestamp":1778655130000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0021925821010267"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":76,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["S0021925821010267"],"URL":"https:\/\/doi.org\/10.1016\/j.jbc.2021.101223","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2020.08.31.274951","asserted-by":"object"}]},"ISSN":["0021-9258"],"issn-type":[{"value":"0021-9258","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"BAP1 and YY1 regulate expression of death receptors in malignant pleural mesothelioma","name":"articletitle","label":"Article Title"},{"value":"Journal of Biological Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jbc.2021.101223","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Inc on behalf of American Society for Biochemistry and Molecular Biology.","name":"copyright","label":"Copyright"}],"article-number":"101223"}}